Corrigendum to “Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study” [Eur Urol 83 (2023) 15–26]

The authors regret that there was an error in the supplementary files – Table 6. The correct values for ‘Severe skin reaction’ are shown below, and also updated online accordingly. [Table presented] The authors would like to apologise for any inconvenience caused.